1. Home
  2. CPT vs HALO Comparison

CPT vs HALO Comparison

Compare CPT & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Camden Property Trust

CPT

Camden Property Trust

HOLD

Current Price

$107.46

Market Cap

11.3B

Sector

Real Estate

ML Signal

HOLD

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

HOLD

Current Price

$107.94

Market Cap

11.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPT
HALO
Founded
1993
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.3B
11.2B
IPO Year
1995
2001

Fundamental Metrics

Financial Performance
Metric
CPT
HALO
Price
$107.46
$107.94
Analyst Decision
Buy
Buy
Analyst Count
17
11
Target Price
$115.28
$78.64
AVG Volume (30 Days)
867.7K
2.3M
Earning Date
04-30-2026
05-05-2026
Dividend Yield
4.03%
N/A
EPS Growth
136.00
N/A
EPS
0.59
3.11
Revenue
$12,967,000.00
$151,862,000.00
Revenue This Year
N/A
$28.24
Revenue Next Year
$2.60
$12.56
P/E Ratio
$182.92
$34.12
Revenue Growth
81.69
N/A
52 Week Low
$96.53
$61.23
52 Week High
$119.81
$107.96

Technical Indicators

Market Signals
Indicator
CPT
HALO
Relative Strength Index (RSI) 39.69 78.97
Support Level $105.41 $67.12
Resistance Level $111.82 N/A
Average True Range (ATR) 1.84 3.59
MACD -0.30 0.96
Stochastic Oscillator 2.87 98.87

Price Performance

Historical Comparison
CPT
HALO

About CPT Camden Property Trust

Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 175 multifamily properties comprised of nearly 59,921 apartment homes across the United States.

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Share on Social Networks: